Unique Technology/Candidates
Boston Immune Technologies and Therapeutics (BITT) is developing a novel class of antagonist antibodies targeting TNF superfamily receptors for applications in oncology, inflammation, autoimmunity, and infectious disease.
Their lead candidate, BIR2101, is a monoclonal antibody that targets tumor necrosis factor receptor 2 (TNFR2). BITT's proprietary antibodies can target cancer cells and their microenvironment, shutting down specific signaling pathways.
Additionally, BITT is developing CD40 antagonists for inflammation and CD30 antagonists for oncology. Their proprietary antibody design platform allows for highly specific targeting of tumors based on unique binding modalities, offering potential benefits in terms of efficacy and reduced side effects compared to traditional treatments.
Most Recent Funding
Series A $10M
- BeiGene, Ltd.
- Hatteras Venture Partners
- EGP Investments
- Hillhouse Capital
Current Clinical Focus
Phase 1 study of BIR2101 (IND approved + IRB approval)
Therapeutic Modality
Monoclonal antibodies
Therapeutic Area / Disease
Oncology / Non-Hodgkin Lymphoma
Autoimmune Disease / Sjögren's syndrome
Company Location
Boston, MA
